Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study [Original Articles]

Conclusions:
Our findings suggest that DPP-4i use did not increase the risk of HF compared with sulfonylurea. In addition, the risks for cardiovascular outcomes were not elevated in DPP-4i–treated patients compared with sulfonylurea-treated patients.

Source: Circulation: Heart Failure - September 12, 2017 Category: Cardiology Authors: Kim, Y.-G., Yoon, D., Park, S., Han, S. J., Kim, D. J., Lee, K.-W., Park, R. W., Kim, H. J. Tags: Cardiovascular Disease, Diabetes, Type 2, Heart Failure Original Articles Source Type: research